Grace Therapeutics Inc. (GRCE)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Grace Therapeutics: Assessing The Path Forward For GTx-104
Grace Therapeutics is rated a Speculative Buy with a $4 price target, implying 57% upside after a sharp drop from a CMC-only FDA CRL. The FDA's concerns for GTx-104 are limited to fixable chemistry, manufacturing, and controls issues, with no efficacy or safety objections raised. A scenario-weighted DCF model assigns a 75% probability of approval, forecasting $100M peak risk-adjusted U.S. sales and highlighting a favorable risk/reward profile.
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
On Monday, Grace Therapeutics, Inc. GRCE, formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipine in patients hospitalized with aneurysmal Subarachnoid Hemorrhage (aSAH).
Grace Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SE Sima Elimelech Activest Wealth Management | 104 | $388.96 | $239.2 | -$149.76 | -38.5% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 1 | $3.75 | $2.3 | -$1.45 | -38.67% |
Grace Therapeutics Inc. (GRCE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Grace Therapeutics Inc. ever had a stock split?
Grace Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Prashant Kohli CEO | NASDAQ (CM) Exchange | 00439U104 CUSIP |
| US Country | 4 Employees | - Last Dividend | 10 Jul 2023 Last Split | 6 May 2011 IPO Date |
Overview
Acasti Pharma Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for rare and orphan diseases. Established in 2002 and based in Laval, Canada, Acasti Pharma is committed to addressing unmet medical needs and improving patient quality of life through its extensive research in pharmacology. The company has been at the forefront of developing unique formulations and delivery mechanisms to ensure both efficiency and safety in treating complex medical conditions.
Products and Services
- GTX-104
An intravenous infusion specially formulated to treat subarachnoid hemorrhage, a life-threatening condition characterized by bleeding in the space surrounding the brain. GTX-104 aims to provide rapid and targeted relief, reducing complications and improving outcomes for patients suffering from this severe type of stroke.
- GTX-102
An innovative oral mucosal spray designed for the treatment of ataxia-telangiectasia, a rare genetic disorder that affects several body systems leading to difficulty with movement and coordination, along with immunodeficiency. GTX-102 seeks to offer a convenient and effective therapy option with the potential to enhance mobility and quality of life for individuals living with this challenging condition.
- GTX-101
A topical bioadhesive film-forming bupivacaine spray being developed for the management of postherpetic neuralgia, a chronic pain condition that can occur after an outbreak of shingles. GTX-101 aims to provide localized pain relief with a novel application method, offering hope for patients seeking alternatives to oral medications or more invasive treatments for their nerve pain.
